Overview

AGN 201904 Versus Esomeprazole in the Prevention of Aspirin-induced Stomach or Upper Intestinal Damage in Healthy Volunteers

Status:
Completed

Trial end date:
2006-08-01

Target enrollment:

Participant gender:

Summary

AGN 201904, a proton pump inhibitor, versus esomeprazole in the prevention of stomach or upper intestinal damage following administration of high-dose aspirin in healthy volunteers

Phase:

Phase 1

Details

Lead Sponsor:

Allergan

Treatments:

Esomeprazole